GENOLUTION INC.

As of June 30, 2026, GENOLUTION INC. carries a market capitalization of 21.87B, placing it among publicly traded companies globally. Its enterprise value stands at 18.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, GENOLUTION INC. has 18.08M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.18, and the price-to-book ratio stands at 0.31.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.81 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 18.12B versus a market cap of 21.87B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, GENOLUTION INC. maintains a current ratio of 1.29, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 34.91, indicating elevated leverage, while an interest coverage ratio of -6.99 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, GENOLUTION INC. posted a negative return on equity (ROE) of -6.46, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.77, reflecting losses generated across the asset base. The company generates approximately 127.79M in revenue per employee across its workforce of 78.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.16 indicates how many times GENOLUTION INC. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, GENOLUTION INC.'s stock has declined approximately 27.52% over the past 52 weeks. The 50-day moving average sits at 1,429.56, while the 200-day moving average is 1,616.91.

Over the twelve months ended June 30, 2026, GENOLUTION INC. generated 10.03B in revenue and converted that into -4.66B in net income, yielding earnings per share of -312.89. EBITDA reached -5.78B, while operating income came in at -7.44B.

As of June 30, 2026, GENOLUTION INC. holds 26.83B in cash and equivalents against 24.03B in total debt, resulting in a net debt position of 5.15B. Total book value stands at 69.78B, with working capital of 7.30B providing operational flexibility.

GENOLUTION INC. produced -3.01B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -388.70M in capital expenditures, free cash flow totaled -3.40B - equivalent to -188.10 per share.

Over the twelve months ended June 30, 2026, GENOLUTION INC. posted a gross margin of 31.98, reflecting its pricing power and cost economics. The operating margin of -74.15 and net profit margin of -46.46 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -15.55: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.40, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to GENOLUTION INC. shareholders.

GENOLUTION INC.'s most recent stock split took place on April 19, 2023 with a 1:2 split ratio.

As of June 30, 2026, GENOLUTION INC. has an Altman Z-Score of 1.14, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.